Jun 11, 2026 07:00AM
Jun 11, 2026 07:00AM
May 12, 2026 07:00AM
Mar 25, 2026 07:00AM
Mar 25, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 23, 2026 07:00AM C4 Therapeutics begins phase 2 trial for multiple myeloma drug
Feb 23, 2026 07:00AM
Jan 14, 2026 07:00AM
Jan 14, 2026 07:00AM
Nov 6, 2025 07:00AM
Sep 20, 2025 11:00AM
Sep 20, 2025 11:00AM
Sep 17, 2025 04:33AM Barclays Reiterates Overweight Rating on C4 Therapeutics (CCCC)
Sep 4, 2025 07:00AM
Aug 7, 2025 07:00AM
May 7, 2025 07:00AM
Nov 5, 2024 07:05AM
Oct 15, 2024 04:03PM
Oct 15, 2024 04:01PM
Sep 13, 2024 10:00AM C4 Therapeutics (CCCC) Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial
Sep 13, 2024 10:00AM
Aug 8, 2023 07:00AM
Jul 5, 2023 07:01AM
Jul 5, 2023 07:00AM
Jun 20, 2023 07:03AM
Jun 20, 2023 07:00AM
May 30, 2023 07:10AM C4 Therapeutics (CCCC), Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGF
May 30, 2023 07:00AM
Nov 3, 2022 07:00AM
Nov 3, 2022 07:00AM
Sep 29, 2022 07:01AM
Sep 29, 2022 07:00AM
Sep 29, 2022 07:00AM
May 16, 2022 08:00AM C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
May 16, 2022 08:00AM
May 5, 2022 08:00AM
May 5, 2022 08:00AM
Mar 9, 2022 08:00AM
Mar 9, 2022 08:00AM
Mar 9, 2022 08:00AM
Feb 24, 2022 07:00AM C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
Feb 24, 2022 07:00AM
Jan 10, 2022 07:03AM
Jan 10, 2022 07:00AM
Jan 10, 2022 07:00AM
Nov 10, 2021 04:01PM
Nov 10, 2021 04:01PM
Aug 11, 2021 04:02PM C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
Aug 11, 2021 04:02PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All